<DOC>
	<DOCNO>NCT00616928</DOCNO>
	<brief_summary>The purpose Phase 3 , observer-blind , placebo-controlled , multi-center study characterize immunogenicity &amp; safety investigation vaccination regimen GSK 1557484A vaccine give adult age ≥18 year .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety GSK 's Influenza Vaccine 1557484A Given Adults Aged ≥18 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female 18 year age great time first vaccination . Written inform consent obtain subject . Among 18 49 year old subject , good general health establish medical history clinical examination enter study . Among subject &gt; 49 year age , stable health status within 1 month prior enrollment . Access consistent mean telephone contact . Comprehension study requirement , ability comprehend comply procedure collection short longterm safety data , express availability require study period , ability willingness attend schedule visit . Evidence substance abuse neurological psychiatric diagnosis , even clinically stable , deemed investigator render potential subjectunable/unlikely provide accurate safety report . Diagnosed cancer , treatment cancer , within 3 year . An oral temperature ≥37.8º C , acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus infection . Receipt systemic glucocorticoid within 1 month study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Any significant disorder coagulation treatment Coumadin derivatives heparin . Administration vaccine within 30 day study enrollment . Previous administration H5N1 vaccine . Use investigational nonregistered product plan participation another investigational study within 30 day prior study enrollment , 364 day follow first test article dose . Use investigational nonregistered product immunosuppressive property exclusionary time trial . Receipt immunoglobulins and/or blood product within 3 month study enrollment plan administration product study period . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin test result prior either vaccination . Lactating nursing . Women child bear potential lack history reliable contraceptive practice . The provision history NOT replace requirement perform , obtain negative result pregnancy urine test prior treatment . Known use analgesic antipyretic medication within 12 hour prior first treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>human</keyword>
	<keyword>safety</keyword>
	<keyword>influenza</keyword>
</DOC>